Cited by 354Cannabis and Cannabinoid ResearchNeurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety

Haller, J., Bakos, N., Szirmay, M., Ledent, C., Freund, T. F.·2002·European Journal of Neuroscience

DOI 10.1046/j.1460-9568.2002.02192.x

Open this paper in CoChat — free account

Abstract

The aim of this study was to compare the effects of the genetic and pharmacological disruption of CB1 cannabinoid receptors on the elevated plus‐maze test of anxiety. In the first experiment, the behaviour of CB1‐knockout mice and wild‐type mice was compared. In the second experiment, the cannabinoid antagonist SR141716A (0, 1, and 3 mg/kg) was administered to both CB1‐knockout and wild type mice. Untreated CB1‐knockout mice showed a reduced exploration of the open arms of the plus‐maze apparatus, thus appearing more anxious than the wild‐type animals, however no changes in locomotion were noticed. The vehicle‐injected CB1‐knockout mice from the second experiment also showed increased anxiety as compared with wild types. Surprisingly, the cannabinoid antagonist SR141716A reduced anxiety in both wild type and CB1 knockout mice. Locomotor behaviour was only marginally affected. Recent evidence suggests the existence of a novel cannabinoid receptor in the brain. It has also been shown that SR141716A binds to both the CB1 and the putative novel receptor. The data presented here supports these findings, as the cannabinoid receptor antagonist affected anxiety in both wild type and CB1‐knockout mice. Tentatively, it may be suggested that the discrepancy between the effects of the genetic and pharmacological blockade of the CB1 receptor suggests that the novel receptor plays a role in anxiety.

Integrity signals

Registry

Crossref · 10.1046/j.1460-9568.2002.02192.x

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Unresponsiveness to Cannabinoids and Reduced Addictive Effects of Opiates in CB 1 Receptor Knockout Mice
Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,628
Self-citation
A review of the validity and variability of the Elevated Plus-Maze as an animal model of anxiety
Hogg, S. (1996) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)02126-4 · Cited by 1,169
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M. A., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,078
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors
Járai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. M., Martin, B. R., Zimmer, A. M., Bonner, T. I., Buckley, N. E., Mezey, É., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.14136 · Cited by 597
Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain
Breivogel, C. S., Griffin, G., Marzo, V. D., & Martin, B. R. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.1.155 · Cited by 538
Involvement of CB1 cannabinoid receptors in emotional behaviour
Martín, M., Ledent, C. A., Parmentier, M., Maldonado, R. J., & Valverde, O. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0946-5 · Cited by 525
Self-citation
Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus
Hájos, N., Ledent, C. A., & Freund, T. F. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00287-1 · Cited by 421
Self-citation
Levels, Metabolism, and Pharmacological Activity of Anandamide in CB1 Cannabinoid Receptor Knockout Mice
Marzo, V. D., Breivogel, C. S., Tao, Q., Bridgen, D. T., Razdan, R. K., Zimmer, A. M., Zimmer, A., & Martin, B. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752434.x · Cited by 394
In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.
Compton, D. M., Aceto, M. D. G., Lowe, J. A., III, & Martin, B. R. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12911-x · Cited by 357
Pharmacological characterization of cannabinoids in the elevated plus maze.
Onaivi, E. S., Green, M. R., & Martin, B. R. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13195-9 · Cited by 312

Show all 26 references

Sorted by citations

The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno‐Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,595
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 978
Neurobiological Interactions Between Stress and the Endocannabinoid System
Morena, M., Patel, S., Bains, J. S., & Hill, M. N. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.166 · Cited by 698
Interneuron Diversity series: Rhythm and mood in perisomatic inhibition
Freund, T. F. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00227-3 · Cited by 641
Self-citation
Endocannabinoid system and stress and anxiety responses
VIVEROS, M., MARCO, E., & FILE, S. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.029 · Cited by 485
From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology
Ligresti, A., PETROCELLIS, L. D., & Marzo, V. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 505
50 years of hurdles and hope in anxiolytic drug discovery
Griebel, G., & Holmes, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4075 · Cited by 430
Pharmacological Evaluation of Cannabinoid Receptor Ligands in a Mouse Model of Anxiety: Further Evidence for an Anxiolytic Role for Endogenous Cannabinoid Signaling
Patel, S., & Hillard, C. J. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.101287 · Cited by 397
Evidence for novel cannabinoid receptors
Begg, M., Pacher, P., Bátkai, S., Osei‐Hyiaman, D., Offertáler, L., Mo, F.-M., LIU, J., & Kunos, G. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.11.005 · Cited by 396
Enhancing Cannabinoid Neurotransmission Augments the Extinction of Conditioned Fear
Chhatwal, J. P., Davis, M., Maguschak, K. A., & Ressler, K. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300655 · Cited by 376
Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: A positron emission tomography study
Neumeister, A., Normandin, M. D., Pietrzak, R. H., Piomelli, D., Zheng, M. Q., Gujarro-Anton, A., Potenza, M. N., Bailey, C. R., Lin, S. F., Najafzadeh, S., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.61 · Cited by 361
Antidepressant-like Activity of the Fatty Acid Amide Hydrolase Inhibitor URB597 in a Rat Model of Chronic Mild Stress
Bortolato, M., Mangieri, R. A., Fu, J., Kim, J. H., Arguello, O., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.001 · Cited by 347
Biphasic Effects of Cannabinoids in Anxiety Responses: CB1 and GABAB Receptors in the Balance of GABAergic and Glutamatergic Neurotransmission
Rey, A. A., Purrio, M., Viveros, M., & Lutz, B. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.123 · Cited by 344
Cannabinoids Elicit Antidepressant-Like Behavior and Activate Serotonergic Neurons through the Medial Prefrontal Cortex
Bambico, F. R., Katz, N., Debonnel, G., & Gobbi, G. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1636-07.2007 · Cited by 325
Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling
Patel, S., Roelke, C. T., Rademacher, D. J., & Hillard, C. J. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03916.x · Cited by 297
The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders
van der Stelt, M., & Marzo, V. D. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.101 · Cited by 292
Context‐dependent effects of CB1 cannabinoid gene disruption on anxiety‐like and social behaviour in mice
Haller, J., Varga, B., Ledent, C., Barna, I., & Freund, T. F. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03293.x · Cited by 284
Self-citation
Best Practice & Research Clinical Endocrinology & Metabolism
Grieb, M. (2009) · Cited by 276
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression
Moreira, F. A., Grieb, M., & Lutz, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.003 · Cited by 277
Cannabinoid Modulation of Amygdala Reactivity to Social Signals of Threat in Humans
Phan, K. L., Angstadt, M., Golden, J., Onyewuenyi, I., Popovska, A., & de Wit, H. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5603-07.2008 · Cited by 251
Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents
Griebel, G., Stemmelin, J., & Scatton, B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.032 · Cited by 253
Differential effects of chronic unpredictable stress on hippocampal CB1 receptors in male and female rats
Reich, C. G., Taylor, M. E., & McCarthy, M. M. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.05.013 · Cited by 244
CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents
Haller, J., Varga, B., Ledent, C., & Freund, T. F. (2004) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000135704.56422.40 · Cited by 241
Self-citation
Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test
Hill, M. N., & Gorzalka, B. B. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.03.003 · Cited by 233
Endocannabinoid system and mood disorders: Priming a target for new therapies
Micale, V., Marzo, V. D., Šulcová, A., Wotjak, C. T., & Drago, F. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.002 · Cited by 224
2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain
Baggelaar, M. P., Maccarrone, M., & van der Stelt, M. (2018) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.05.002 · Cited by 224
Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors
Urigüen, L., Pérez-Rial, S., Ledent, C., Palomo, T., & Manzanares, J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.01.003 · Cited by 218
Self-citation
Cannabis and psychiatric disorders: it is not only addiction
Leweke, F. M., & Koethe, D. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00106.x · Cited by 213
Effects of endocannabinoid system modulation on cognitive and emotional behavior
Zanettini, C. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00057 · Cited by 214
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?
Hill, M. N., & Gorzalka, B. B. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00006 · Cited by 196
Cannabinoid receptor 1 (CNR1) gene: Impact on antidepressant treatment response and emotion processing in Major Depression
Domschke, K., Dannlowski, U., Ohrmann, P., Lawford, B. R., Bauer, J., Kugel, H., Heindel, W. L., Young, R. M., Morris, C. P., Arolt, V., et al. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.05.003 · Cited by 189
Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice
Shearman, L. P., Rosko, K., Fleischer, R., Wang, J., Xu, S., Tong, X., & Rocha, B. A. G. (2003) · Behavioural Pharmacology · doi:10.1097/00008877-200312000-00001 · Cited by 188
Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality
Naidu, P. S., Varvel, S. A., Ahn, K., Cravatt, B. F., Martin, B. R., & Lichtman, A. H. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0689-4 · Cited by 184
A critical inquiry into marble-burying as a preclinical screening paradigm of relevance for anxiety and obsessive–compulsive disorder: Mapping the way forward
de Brouwer, G., Fick, A., Harvey, B. H., & Wolmarans, D. W. (2018) · Cognitive Affective & Behavioral Neuroscience · doi:10.3758/s13415-018-00653-4 · Cited by 198
Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors
Serrano, A., & Parsons, L. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.06.005 · Cited by 188
Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats
Sciolino, N. R., Zhou, W., & Hohmann, A. G. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.010 · Cited by 179
Pharmacological treatments that facilitate extinction of fear: Relevance to psychotherapy
Davis, M., Myers, K. M., Chhatwal, J., & Ressler, K. J. (2006) · NeuroRX · doi:10.1016/j.nurx.2005.12.008 · Cited by 174
Cannabinoid receptor activation in the basolateral amygdala blocks the effects of stress on the conditioning and extinction of inhibitory avoidance
Ganon-Elazar, E., & Akirav, I. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1223-09.2009 · Cited by 173
Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis
Steiner, M. S., & Wotjak, C. T. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00433-0 · Cited by 174
Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors
Bilkei‐Gorzó, A., Rácz, I., Valverde, O., Otto, M., Michel, K., Sarstre, M., & Zimmer, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504640102 · Cited by 166
A role for cannabinoid CB1 receptors in mood and anxiety disorders
Witkin, J. M., Tzavara, E. T., & Nomikos, G. G. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00005 · Cited by 160
Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice
García-Gutiérrez, M. S., & Manzanares, J. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379507 · Cited by 153
CB1 receptor-deficient mice as a model for depression
Valverde, O., & Torrens, M. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.09.031 · Cited by 156
The endocannabinoid system and psychiatric disorders
Parolaro, D., Realini, N., Viganò, D., Guidali, C., & Rubino, T. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.03.018 · Cited by 151
PTSD: from neurobiology to pharmacological treatments
Kelmendi, B., Adams, T., Yarnell, S. C., Southwick, S., Abdallah, C., & Krystal, J. (2016) · European Journal of Psychotraumatology · doi:10.3402/ejpt.v7.31858 · Cited by 136
Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice
Steiner, M. A., Marsicano, G., Nestler, E. J., Holsboer, F., Lutz, B., & Wotjak, C. T. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.09.008 · Cited by 146
Endocannabinoid System and Synaptic Plasticity: Implications for Emotional Responses
Viveros, M., Marco, E. M., Llorente, R., & López‐Gallardo, M. (2007) · Neural Plasticity · doi:10.1155/2007/52908 · Cited by 151
Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases
Haspula, D., & Clark, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207693 · Cited by 148
Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects
Marco, E. M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00063 · Cited by 139
The individuality of mice
Lathe, R. (2004) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2004.00083.x · Cited by 138
The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction
Lafenêtre, P., Chaouloff, F., & Marsicano, G. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.006 · Cited by 143
Endocannabinoid System Components as Potential Biomarkers in Psychiatry
Navarrete, F., García‐Gutiérrez, M. S., Barba, R. J., Rubio, G., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00315 · Cited by 146
Alterations in Corticolimbic Dendritic Morphology and Emotional Behavior in Cannabinoid CB1 Receptor-Deficient Mice Parallel the Effects of Chronic Stress
Hill, M. N., Hillard, C. J., & McEwen, B. S. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhq280 · Cited by 136
The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze
Takahashi, R. N., Pamplona, F. A., & Fernandes, M. S. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.01.049 · Cited by 127
To Predict, Prevent, and Manage Post-Traumatic Stress Disorder (PTSD): A Review of Pathophysiology, Treatment, and Biomarkers
Jowf, G. I. A., Ahmed, Z. T., Reijnders, R. A., de Nijs, L., & Eijssen, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065238 · Cited by 145
Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice
Steiner, M. A., Wanisch, K., Monory, K., Marsicano, G., Borroni, E., Bächli, H., Holsboer, F., Lutz, B., & Wotjak, C. T. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500466 · Cited by 130
Opposing Roles for Cannabinoid Receptor Type-1 (CB1) and Transient Receptor Potential Vanilloid Type-1 Channel (TRPV1) on the Modulation of Panic-Like Responses in Rats
Casarotto, P. C., Terzian, A. L. B., Aguiar, D. C., Zangrossi, H., Guimarães, F. S., Wotjak, C. T., & Moreira, F. A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.207 · Cited by 117
Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants
Gorzalka, B. B., & Hill, M. N. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.021 · Cited by 120
Role of the endocannabinoid system in drug addiction
Manzanares, J., Cabañero, D., Puente, N., García‐Gutiérrez, M. S., Grandes, P., & Maldonado, R. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.013 · Cited by 118
5-HT1A receptors are involved in the anxiolytic effect of Δ9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague–Dawley rats
Braida, D., Limonta, V., Malabarba, L., Zani, A., & Sala, M. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.10.038 · Cited by 117
Enhancement of anxiety-like responsiveness to the cannabinoid CB1 receptor agonist HU-210 following chronic stress
Hill, M. N., & Gorzalka, B. B. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.06.069 · Cited by 119
Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs
Nathan, P. J., O’Neill, B. V., Napolitano, A., & Bullmore, E. T. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00172.x · Cited by 115
Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole – LH 21
Pavón, F. J., Bilbao, A., Hernández‐Folgado, L., Cippitelli, A., Jagerovic, N., Abellán, G., Rodríguez-Franco, M. I., Serrano, A., Macías, M., de Heras, R. G., et al. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.03.029 · Cited by 115
Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses
Hill, M. N., & Patel, S. (2013) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-3-19 · Cited by 120
Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety—two sides of one coin?
Moreira, F. A., de Aguiar, D. C., Terzian, A. L. B., Guimarães, F. S., & Wotjak, C. T. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.046 · Cited by 113
Cannabinoids and the Brain
Köfalvi, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3 · Cited by 110
Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission
Haller, J., Mátyás, F., Soproni, K., Varga, B., Barsy, B., Németh, B., Mikics, É., Freund, T. F., & Hájos, N. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05476.x · Cited by 103
Self-citation
Anandamide hydrolysis: a new target for anti-anxiety drugs?
Gaetani, S., Cuomo, V., & Piomelli, D. (2003) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.09.005 · Cited by 104
The Role of Cannabinoids in Modulating Emotional and Non-Emotional Memory Processes in the Hippocampus
Akirav, I. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00034 · Cited by 102
The Clinical Implications of Mouse Models of Enhanced Anxiety
Sartori, S. B., Landgraf, R., & Singewald, N. (2011) · Future Neurology · doi:10.2217/fnl.11.34 · Cited by 103
Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-na??ve and plus-maze-experienced mice
Rodgers, R. J., Evans, P., & Murphy, A. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00013 · Cited by 101
The Association between Regular Cannabis Exposure and Alterations of Human Brain Morphology: An Updated Review of the Literature
Lorenzetti, V., Solowij, N., Fornito, A., Lubman, D. I., & Yücel, M. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990435 · Cited by 99
Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission
Jacob, W., Yassouridis, A., Marsicano, G., Monory, K., Lutz, B., & Wotjak, C. T. (2009) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2009.00512.x · Cited by 95
Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain
Porta, C. L., Bura, S. A., Llorente‐Onaindia, J., Pastor, A., Navarrete, F., García‐Gutiérrez, M. S., de la Torre, R., Manzanares, J., Monfort, J., & Maldonado, R. J. (2015) · Pain · doi:10.1097/j.pain.0000000000000260 · Cited by 97
Endocannabinoid-mediated synaptic plasticity and addiction-related behavior
Sidhpura, N., & Parsons, L. H. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.034 · Cited by 92
Endocannabinoids in the Treatment of Mood Disorders: Evidence from Animal Models
Bambico, F. R., Duranti, A., Tontini, A., Tarzia, G., & Gobbi, G. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168029 · Cited by 94
Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test
Genn, R. F., Tucci, S. A., Marco, E. M., Viveros, M., & File, S. E. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2003.12.019 · Cited by 92
The endocannabinoid system as a target for the treatment of cannabis dependence
Clapper, J. R., Mangieri, R. A., & Piomelli, D. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.018 · Cited by 94
Recent Progress in Understanding the Pathophysiology of Post-Traumatic Stress Disorder: Implications for Targeted Pharmacological Treatment
Bailey, C. R., Cordell, E., Sobin, S. M., & Neumeister, A. (2013) · CNS Drugs · doi:10.1007/s40263-013-0051-4 · Cited by 89
‘One‐trial sensitization’ to the anxiolytic‐like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus‐maze
Rodgers, R. J., Haller, J., Halász, J., & Mikics, É. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02548.x · Cited by 88
Self-citation
Cannabinoid Receptor Activation Prevents the Effects of Chronic Mild Stress on Emotional Learning and LTP in a Rat Model of Depression
Segev, A., Rubin, A. S., Abush, H., Richter‐Levin, G., & Akirav, I. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.292 · Cited by 90
Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers
Horder, J., Harmer, C. J., Cowen, P. J., & McCabe, C. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000453 · Cited by 89
Endocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance
Finn, D. P. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.05.011 · Cited by 91
Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142
Sink, K. S., Segovia, K. N., Sink, J. R., Randall, P. A., Collins, L. E., Correa, M., Markus, E. J., Vemuri, K. V., Makriyannis, A., & Salamone, J. D. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.11.002 · Cited by 89
Endocannabinoids, cannabinoids and the regulation of anxiety
Petrie, G. N., Nastase, A. S., Aukema, R. J., & Hill, M. N. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108626 · Cited by 91
Constitutive increases in amygdalar corticotropin-releasing factor and fatty acid amide hydrolase drive an anxious phenotype
Natividad, L. A., Buczynski, M. W., Herman, M. A., Kirson, D., Oleata, C. S., Irimia, C., Polis, I., Ciccocioppo, R., Roberto, M., & Parsons, L. H. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.01.005 · Cited by 84
Chapter 5 The Endocannabinoid System as A Target for Novel Anxiolytic and Antidepressant Drugs
Gaetani, S., Dipasquale, P., Romano, A., Righetti, L., Cassano, T., Piomelli, D., & Cuomo, V. (2009) · International Review of Neurobiology · doi:10.1016/s0074-7742(09)85005-8 · Cited by 83
The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD)
Trezza, V., & Campolongo, P. (2013) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2013.00100 · Cited by 87
Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice
Naderi, N., Haghparast, A., Saber-Tehrani, A. S., Rezaii, N., Alizadeh, A.-M., Khani, A., & Motamedi, F. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.11.001 · Cited by 87
Involvement of Nitric Oxide in Depolarization-Induced Suppression of Inhibition in Hippocampal Pyramidal Cells during Activation of Cholinergic Receptors
Makara, J. K., Katona, I., Nyíri, G., Németh, B., Ledent, C. A., Watanabe, M., de Vente, J., Freund, T. F., & Hájos, N. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.2104-07.2007 · Cited by 84
Self-citation
Role of Endocannabinoid Signaling in Anxiety and Depression
Patel, S., & Hillard, C. J. (2009) · Current topics in behavioral neurosciences · doi:10.1007/978-3-540-88955-7_14 · Cited by 91
Differential Effects of Single Versus Repeated Alcohol Withdrawal on the Expression of Endocannabinoid System‐Related Genes in the Rat Amygdala
Serrano, A., Rivera, P., Pavón, F. J., Decara, J. M., Suárez, J., de Fonseca, F. R., & Parsons, L. H. (2011) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01686.x · Cited by 86
The effects of trauma on brain and body: A unifying role for the midbrain periaqueductal gray
Terpou, B. A., Harricharan, S., McKinnon, M. C., Frewen, P., Jetly, R., & Lanius, R. A. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24447 · Cited by 82
Cannabinoids and emotionality: a neuroanatomical perspective
McLaughlin, R. J., & Gobbi, G. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.07.052 · Cited by 84
Personalized medicine can pave the way for the safe use of CB1 receptor antagonists
Lazáry, J., Juhász, G., Hunyady, L., & Bagdy, G. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.02.013 · Cited by 84
Reviewing the Role of the Endocannabinoid System in the Pathophysiology of Depression
Gallego‐Landin, I., García-Baos, A., Castro‐Zavala, A., & Valverde, O. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.762738 · Cited by 85
The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1receptor antagonism ? or inverse agonism ? as potential obesity treatment and other therapeutic use
Xie, S., Furjanic, M. A., Ferrara, J., McAndrew, N. R., Ardino, E. L., Ngondara, A., Bernstein, Y., Thomas, K. J., Kim, E., Walker, J. M., et al. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00817.x · Cited by 82

Authors: Haller, J., Bakos, N., Szirmay, M., Ledent, C., & Freund, T. F.
Affiliations: HUN-REN Institute of Experimental Medicine (HU)
Université Libre de Bruxelles (BE)
Corresponding author: Freund, T. F.
ORCID: Haller, J.
Ledent, C.
Venue: European Journal of Neuroscience
Publisher: Wiley
Published: 2002-10
Volume: 16
Issue: 7
Pages: 1395-1398
ISSN: 0953-816X (ISSN-L)
1460-9568
DOI: 10.1046/j.1460-9568.2002.02192.x
OpenAlex: W2027352187
Cited by: 354
References: 26
Citations by year: 2026: 5 · 2025: 10 · 2024: 5 · 2023: 14 · 2022: 6 · 2021: 14 · 2020: 9 · 2019: 8 · 2018: 11 · 2017: 13 · 2016: 11 · 2015: 16 · 2014: 16 · 2013: 18 · 2012: 18
FWCI: 9.01
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 28 d)
Locations: European Journal of Neuroscience (publishedVersion)
PubMed (publishedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
Funders: Hungarian Scientific Research Fund
National Institute of Mental Health (R01MH054671, MH54671)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords: CB1 receptor, anxiety, CB1 knockout mice, SR141716A, cannabinoid receptor antagonists, elevated plus maze, locomotor behaviour
MeSH terms: Rimonabant, Animals, Anxiety, Exploratory Behavior, Motor Activity, Piperidines, Pyrazoles, Receptors, Drug, Mice, Knockout, Maze Learning, Receptors, Cannabinoid, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks